SCHEMBL2882862

SCHEMBL2882862

C[Si](C)(C)CCOCn1ccc2c(Cc3ccc(NC(=O)C(F)(F)F)cc3F)ccnc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.37
BRAF P15056 1/20 0.34
MAPT P10636 1/20 0.34
EPHX2 P34913 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
MTNR1B P49286 1/20 0.33
PPARG P37231 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
NPY5R Q15761 3/20 0.32
ABL1 P00519 2/20 0.32
BCR P11274 1/20 0.32
GPR39 O43194 1/20 0.32
AR P10275 1/20 0.32
CSF1R P07333 2/20 0.31
PDGFRB P09619 1/20 0.31
PDGFRA P16234 1/20 0.31
LCK P06239 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2882722 0.85 EPHX2 (0.35) METBRAFMAPTEPHX2SMN1; SMN2
SCHEMBL2885789 0.85 MET (0.34) METBRAFMAPTEPHX2SMN1; SMN2
SCHEMBL4767965 0.82 MET (0.37) METBRAFKITSRCKDR
SCHEMBL2886193 0.80 ADRA2B (0.33)
SCHEMBL25290554 0.75 MET (0.44) METFLT1FLT4KDR
SCHEMBL29837318 0.74 MET (0.43) METKDRFLT3
SCHEMBL25793121 0.74 MET (0.43) METKDRFLT3
SCHEMBL20418535 0.73 SMN1; SMN2 (0.41) MAPTSMN1; SMN2MTNR1BCYP1A2CYP2C9
SCHEMBL29821745 0.72 MET (0.37) METKITSRCKDR
SCHEMBL21632543 0.72 MAPT (0.35) MAPTSMN1; SMN2SRCFLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
EP-1742945-B1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER SCHERING PHARMA AG (DE) 2009-12-30 EP disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
EP-1742945-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES Bayer HealthCare AG (DE) 2007-01-17 EP disclosed
WO-2005108397-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER HEALTHCARE AG (DE) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269268-A1 Substituted Phenylamino-Pyrimidines TYMP, DPYD, HPRT1 MET 3468/4885BRAF 1110/4885MAPT 3319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.